Biovitrum to start Phase IIb obesity study

Biovitrum (Stockholm, Sweden) said it would start after Christmas a three-month, 150-patient, placebo-controlled Swedish Phase IIb dose-finding study of its BVT-933 5HT2C receptor agonist to treat obe...